|
Mixed model repeated measure linear regression showing the association between NT-proBNP (dependent variable) and markers of disease activity and treatment |
||||
| Adjusted linear regression (CI) |
Multivariate linear regression (CI) |
|||
|
|
||||
| β coefficients (CI) |
P value |
β coefficients (CI) |
P value |
|
|
|
||||
| Age |
1.03 (1.02–1.03) |
< 0.001 |
1.02 (1.01–1.02) |
< 0.001 |
| Male gender |
0.81 (0.64–1.01) |
0.06 |
0.12 (0.05–0.26) |
< 0.001 |
| C-reactive proteina |
1.01 (1.01–1.02) |
< 0.001 |
1.01 (1.01–1.02) |
< 0.001 |
| HAQa |
1.12 (1.00–1.27) |
0.06 |
||
| Prednisolonea, b |
1.20 (1.03–1.41) |
0.02 |
||
| NSAIDa, b |
0.90 (0.79–1.04) |
0.14 |
||
| DMARDa, b |
0.95 (0.83–1.09) |
0.49 |
||
| Sharp scorea |
1.01 (1.00–1.01) |
0.001 |
||
| Ritchie scorea |
1.01 (1.00–1.02) |
0.01 |
||
| Time |
1.04 (1.03–1.06) |
< 0.001 |
1.03 (1.02–1.05) |
< 0.001 |
| Time × male gender |
1.04 (1.01–1.07) |
0.01 |
||
| Age × male gender |
1.03 (1.02–1.05) |
0.01 |
||
|
aAge- and gender-adjusted; bdichotomized variable. CI, confidence interval; DMARD, disease-modifying anti-rheumatic drug; HAQ, Stanford Health Assessment Questionnaire; NSAID, non-steroidal anti-inflammatory drug; NT-proBNP, N-terminal pro-brain natriuretic peptide; Ritchie score, Ritchie articular index; Sharp score, van der Heijde modified Sharp criteria. | ||||
Provan et al. Arthritis Research & Therapy 2008 10:R70 doi:10.1186/ar2442 |
||||